Recent pioneering research has enhanced precision and efficacy in cancer therapies. A novel fusion protein developed by the University of Basel synergizes immune checkpoint blockade with tumor-selective immune activation to overcome cancer immune evasion. Concurrently, engineers at MIT have refined prime editing tools to dramatically reduce unintended genomic edits, improving safety in gene therapies. These dual advances represent critical steps toward safer, more effective oncological treatments and genetic interventions.